| 000 | 01717 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250517235154.0 | ||
| 264 | 0 | _c20190820 | |
| 008 | 201908s 0 0 eng d | ||
| 022 | _a1720-8386 | ||
| 024 | 7 |
_a10.1007/s40618-018-0947-4 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLopes-Ventura, S | |
| 245 | 0 | 0 |
_aThe efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines. _h[electronic resource] |
| 260 |
_bJournal of endocrinological investigation _cMay 2019 |
||
| 300 |
_a527-540 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology |
| 650 | 0 | 4 | _aApoptosis |
| 650 | 0 | 4 | _aCell Cycle |
| 650 | 0 | 4 | _aCell Proliferation |
| 650 | 0 | 4 |
_aCyclin-Dependent Kinase 4 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aCyclin-Dependent Kinase 6 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aGene Expression Regulation, Neoplastic _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aPiperazines _xadministration & dosage |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins p21(ras) _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPyridines _xadministration & dosage |
| 650 | 0 | 4 |
_aQuinolones _xadministration & dosage |
| 650 | 0 | 4 |
_aThyroid Carcinoma, Anaplastic _xdrug therapy |
| 650 | 0 | 4 |
_aThyroid Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 700 | 1 | _aPojo, M | |
| 700 | 1 | _aMatias, A T | |
| 700 | 1 | _aMoura, M M | |
| 700 | 1 | _aMarques, I J | |
| 700 | 1 | _aLeite, V | |
| 700 | 1 | _aCavaco, B M | |
| 773 | 0 |
_tJournal of endocrinological investigation _gvol. 42 _gno. 5 _gp. 527-540 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s40618-018-0947-4 _zAvailable from publisher's website |
| 999 |
_c28812183 _d28812183 |
||